Loading patent…
AssigneeSorrento Therapeutics, Inc.
InventorsHenry Hongjun Ji, Robert Allen, Heyue Zhou, Yanliang Zhang, Yanwen Fu, Wenzhong Guo, Hui Xie, Xia Cao, Lucy Lu, Donghui Li, Reyna Lim, Arthur Ledesma, Daniel Lee
Estimating the term…
The present disclosure provides fully human antibodies that specifically bind the spike (S) protein of the SARS-CoV-2 coronavirus with high affinity, or antigen-binding proteins derived from such antibodies, and uses thereof. Included are anti-spike protein antibodies, antibody fragments, and single-chain antibodies, that are coronavirus neutralizing antibodies, as well as pharmaceutical compositions that include such antibodies and antibody fragments. Methods for using the anti-spike protein antibodies include methods of treating or preventing infection with a coronavirus, such as the SARS-CoV-2 coronavirus, by administering an antibody or antibody fragment as disclosed herein, including by intranasal delivery. Methods and compositions for treating or preventing coronavirus infection by administering a composition that includes a nucleic acid construct that encodes a neutralizing antibody are also provided.
An isolated antigen-binding protein that specifically binds the spike (S) protein of SARS-CoV-2, wherein the antigen-binding protein comprises a heavy chain variable domain having at least 95% sequence identity to the amino acid sequence of SEQ ID NO:28 and a light chain variable domain having at least 95% sequence identity to the amino acid sequence of SEQ ID NO:29.
An isolated antigen-binding protein that specifically binds the S protein of SARS-CoV-2, comprising a heavy chain complementarity determining region (CDR) 1 having the amino acid sequence of SEQ ID NO:30, a heavy chain CDR2 having the amino acid sequence of SEQ ID NO:31, a heavy chain CDR3 having the amino acid sequence of SEQ ID NO:32, a light chain CDR1 having the amino acid sequence of SEQ ID NO:33, a light chain CDR2 having the amino acid sequence of SEQ ID NO:34, and a light chain CDR3 having the amino acid sequence of SEQ ID NO:35.
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
A composition comprising at least one nucleic acid molecule that comprises a nucleic acid sequence encoding a polypeptide comprising a heavy chain variable region having at least 95% identity to SEQ ID NO:28 and a nucleic acid sequence encoding a polypeptide comprising a light chain variable region having at least 95% identity to SEQ ID NO:29.
(canceled)
A method of treating or preventing a coronavirus infection, comprising:
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
Dependencies are inferred from the claim text.